Molecular pharmacology of adipocyte-secreted autotaxin

Chemico-Biological Interactions

Volumn 172, Issue 2, 2008, Pages 115-124

  Moulharat, Natacha ^a   Fould, Benjamin ^a   Giganti, Adeline ^a   Boutin, Jean A ^a   Ferry, Gilles ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Autotaxin; Inhibition; Lyso phosphatidylcholine; Phosphodiesterase; Purification

Indexed keywords

3 ISOBUTYL 1,4,3',4' (METHYLENEDIOXY)BENZYLAMINO 6 METHOXYQUINAZOLINE; 3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4,3',4' (METHYLENEDIOXY)BENZYLAMINO 6 METHOXYQUINAZOLINE; ADENOSINE TRIPHOSPHATE; ALCOHOL; AUTOTAXIN; CALMIDAZOLIUM; DAMNACANTHAL; EDETIC ACID; HYPERICIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE; MILRINONE; NITRENDIPINE; PAPAVERINE; PENTOXIFYLLINE; PHENANTHROLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHONIC ACID ESTER; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SPHINGOSINE 1 PHOSPHATE; TREQUINSIN; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SUBSTRATE; NONHUMAN;

EID: 40349094673     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.01.001     Document Type: Article

References (49)

1. S. Gesta M. Simon A. Rey D. Sibrac A. Girard M. Lafontan P. Valet J.S. Saulnier-Blache Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis J. Lipid Res. 43 2002 904 910
2. G. Tigyi Physiological responses to lysophosphatidic acid and related glycero-phospholipids, Prostagland Other Lipid Mediat. 64 2001 47 62
3. D.B. Hausman M. DiGirolamo T.J. Bartness G.J. Hausman R.J. Martin The biology of white adipocyte proliferation Obes. Rev. 2 2001 239 254
4. D. Meyer zu Heringdorf K.H. Jakobs Lysophopholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism Biochim. Biophys. Acta 2006 (Epub ahead of print)
5. M. Umezu-Goto Y. Kishi A. Taira K. Hama N. Domhmae K. Takio T. Yamori G.B. Mills K. Inoue J. Aoki H. Arai Autotaxin has klysopholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J. Cell. Biol. 158 2002 227 233
6. A. Tokumura E. Majima Y. Kariya K. Tominaga K. Kogure K. Yasuda K. Fukuzawa Identification of human palsma lysopholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin a multifunctional phosphodiesterase J. Biol. Chem. 277 2002 39436 39442
7. G. Ferry E. Tellier A. Try S. Gres I. Naime M.F. Simon M. Rodriguez J. Boucher I. Tack S. Gesta P. Chomarat M. Dieu P. Maes J.P. Galizzi P. Valet J.A. Boutin J.S. Saulnier-Blache Autotaxin is released from adipocytes, catalyses lysophosphatidic acid synthesis and activates preadipocyte proliferation: up-regulated expression with adipocytes differentiation and obesity J. Biol. Chem. 278 2003 18162 18168
8. T. Clair H.Y. Lee L.A. Liotta M.L. Stracke Autotaxin is an exoenzyme possessing 5′-nucleotide phosphodiesterase/ATP pyrophosphatease and ATPase activities J. Biol. Chem. 272 1997 996 1001
9. J. Murata H.Y. Lee T. Clair H.C. Krutzsch A.A. Arestad M.E. Sobel L.A. Liotta M.L. Stracke cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases J. Biol. Chem. 269 1994 30479 30484
10. H.Y. Lee J. Murata T. Clair M.H. Polymeropoulos R. Torres R.E. Manrow L.A. Liotta M.L. Stracke Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells Biochem. Biophys. Res. Commun. 218 1996 714 719
11. H. Kawagoe O. Soma J. Goji N. Nishimura M. Narita J. Inazawa H. Nakamura K. Sano Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2) Genomics 20 1995 380 384
12. P. Valet C. Pages O. Jeanneton D. Daviaud P. Barbe M. Record J.S. Saulnier-Blache M. Lafontan Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth J. Clin. Invest. 101 1998 1431 1438
13. J. Boucher D. Quilliot J.P. Praderes M.F. Simon S. Gres C. Guigne D. Prevot G. Ferry J.A. Boutin C. Carpene P. Valet J.S. Saulnier-Blache Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression Diabetologia 48 2005 569 577
14. A. Boucharaba C. Serre S. Gres J.S. Saulnier-Blache J.C. Bordet J. Guglielmi P. Clezardin O. Peyruchaud Platelet-derivated lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer J. Clin. Invest. 114 2004 1714 1725
15. L.A. van Meeteren P. Ruurs E. Christodoulou J.W. Goding H. Takakusa K. Kikuchi A. Perrakis T. Nagano W.H. Moolenaar Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate J. Biol. Chem. 280 2005 21155 21161
16. G.G. Durgam T. Virag M.D. Walker R. Tsukahara S. Yasuda K. Liliom L.A. van Meeteren W.H. Moolenaar N. Wilke W. Siess G. Tigyi D.D. Miller Synthesis, structure–activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin J. Med. Chem. 48 2005 4919 4930
17. D.L. Baker Y. Fujiwara K.R. Pigg R. Tsukahara S. Kobayashi H. Murofushi A. Uchiyama K. Muramaki-Murofushi E. Koh R.W. Bandle H.S. Byun R. Bittman D. Fan M. Murph G.B. Mills G. Tigyi Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis J. Biol. Chem. 281 2006 22786 22793
18. P. Cui J.L. Tomsig W.F. McCalmont S. Lee C.J. Becker K.R. Lynch T.L. Macdonald Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors Bioorg. Med. Chem. Lett. 7 2007 1634 1640
19. J.A. Boutin Tyrosine protein kinase inhibition and cancer Int. J. Biochem. 26 1994 1203 1226
20. A. Tokumura M. Miyake O. Yoshimoto M. Shimizu K. Fukuzawa Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma Lipids 33 1998 1009 1015
21. R. Gijsbers J. Aoki H. Arai M. Bollen The hydrolysis of phospholipids and nucleotides by autotaxin (NPP2) involves a signle catalytic site FEBS Lett. 538 2003 60 64
22. W.E. Razzell H.G. Khorana Studies on polynucleotides. III. Enzymic degradation; substrate specificity and properties of snake venom phosphodiesterase J. Biol. Chem. 234 1959 2105 2113
23. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
24. A. Shevchenko M. Wilm O. Vorm M. Mann Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels Anal. Chem. 68 1996 850 858
25. I.C. Segel Enzyme Kinetics 1975 Wiley Intersciences New York, NY
26. T. Clair J. Aoki E. Koh R.W. Bandle S.W. Nam M.M. Ptaszynska G.B. Mills E. Schiffmann L.A. Liotta M.L. Stracke Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate Cancer Res. 63 2003 5446 5453
27. J.N. Wells J.R. Miller Methylxanthine inhibitors of phosphodiesterases Methods Enzymol. 159 1988 489 496
28. 2+-ATPase in cardiac sarcolemma by the anti-calmodulin drug calmidazolium Cell Calcium 4 1983 281 294
29. M. Hagiwara T. Endo H. Hidaka Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle Biochem. Pharmacol. 33 1984 453 457
30. 2+ current in rat ventricular myocytes Br. J. Pharmacol. 127 1999 65 74
31. M. Holck S. Thorens R. Muggli R. Eigenmann Studies on the mechanism of positive inotropic activity of RO 13-6438, a structurally novel cardiotonic agent with vasodilating properties J. Cardiovasc. Pharmacol. 6 1984 520 530
32. H.R. Weiss G.X. Gong M. Straznicka L. Yan J. Tse P.M. Scholz Cyclic GMP and cyclic AMP-induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases Can. J. Physiol. Pharmacol. 77 1999 422 431
33. M.L. Reeves B.K. Leigh P.J. England The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors Biochem. J. 241 1987 535 541
34. F. Burns I.W. Rodger N.J. Pyne The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung Biochem. J. 283 1992 487 491
35. Y. Takase T. Saeki N. Watanabe H. Adachi S. Souda I. Saito Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity J. Med. Chem. 37 1994 2106 2111
36. D. Ruppert K.U. Weithmann HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro Life Sci. 31 1982 2037 2043
37. J.A. Beavo D.H. Reifsnyder Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors Trends Pharmacol. Sci. 11 1990 150 155
38. I. Perry S.M. Buttrum G.B. Nash Effect of activation on adhesion of flowing neutrophils to cultured endothelium: time course and inhibition by a calcium channel blocker (nitrendipine) Br. J. Pharmacol. 110 1993 1630 1634
39. M. Monshouwer R.A. McLellan E. Delaporte R.F. Witkamp A.S.J.P.A.M. van Miert K.W. Renton Differential effect of pentoxifylline on lipopolysaccharide-induced downregulation of cytochrome p450 Biochem. Pharmacol. 52 1996 1195 1200
40. H. Bergstrand J. Kristoffersson B. Lundquist A. Schurmann Effects of antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate phosphodiesterases Mol. Pharmacol. 13 1977 38 43
41. J.S. Saulnier-Blache A. Girard M.F. Simon M. Lafontan P. Valet A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification J. Lipid. Res. 41 2000 1947 1951
42. A. Levitzki Protein tyrosine kinase inhibitors as novel therapeutic agents Pharmacol. Ther. 82 1999 231 239
43. C. Luquain A. Singh L. Wang V. Natarajan A.J. Morris Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells J. Lipid Res. 44 2003 1075 1963
44. D. Bachner M. Ahrens N. Betat D. Scröder G. Gross Developmental expression analysis of murine autotaxin (ATX) Mech. Dev. 84 1999 121 125
45. C.R. Faltynek J. Schroeder P. Mauvais D. Miller S. Wang D. Murphy R. Lehr M. Kelley A. Maycock W. Michne Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity Biochemistry 34 1995 12404 12410
46. G. Jiang Y. Xu Y. Fujiwara T. Tsukahara R. Tsukahara J. Gajeiak G. Tigyi G.D. Prestwich A-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA ChemMedChem 2 2007 679 690
47. S.Y. Yang J. Lee C.G. Park S. Kim S. Hong H.C. Chung S.K. Min J.W. Han W. Lee H.Y. Lee Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells Clin. Exp. Metast. 19 2002 603 608
48. D.N. Brindley Lipid phosphate phosphatases and related proteins: signalling functions in development, cell division and cancer J. Cell. Biochem. 92 2004 900 912
49. G.W. Mayr S. Windhorst K. Hillemeier Antiproliferative plant and synthetic polyphenolics are specific inhibitors of vertebrate inositol-1,4,5-trisphosphate 3-kinases and inositol polyphosphate multikinase J. Biol. Chem. 280 2005 13229 13240